On January 11, 2022 Panavance Therapeutics Inc. ("Panavance") is a new clinical-stage pharmaceutical company reported that created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications (Press release, Panavance Therapeutics, JAN 11, 2022, View Source [SID1234598602]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
GP-2250 is a broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell death. Panavance’s initial clinical focus is on pancreatic cancer, and the company is conducting preclinical studies to develop GP-2250 for the treatment of other cancers and therapeutic indications.
"Panavance was established by Avensis Pharma AG to pursue the development of GP-2250, a novel compound with great potential. This molecule has demonstrated effectiveness and safety in preclinical studies, and its early clinical results in a Phase 1/2 pancreatic cancer trial across 4 US clinical sites have been encouraging," said Greg Bosch, Chairman & Chief Executive Officer of Panavance.
"We believe in the potential of GP-2250, and the Panavance team is dedicated to realizing its therapeutic possibilities, starting with pancreatic and gynecological cancers, both of which represent areas with unmet clinical need. Ultimately, we hope to improve and extend the lives of cancer patients."
To accelerate its capitalization, development, and success, Panavance has assembled an impressive leadership team, board of directors, and clinical and scientific advisors, which include seasoned leaders with life science backgrounds in pharmaceutical drug development, clinical and medical sciences, commercialization, and capital markets.
Learn more about Panavance and GP-2250 at www.panavance.com.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Panavance is not responsible for the contents of third-party websites.